[
    [
        {
            "time": "2018-03-15",
            "original_text": "Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Opdivo-Yervoy",
                    "NSCLC",
                    "Application",
                    "Withdrawn"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others",
            "features": {
                "keywords": [
                    "Q4",
                    "Earnings",
                    "Scorecard",
                    "Analyst",
                    "Reports",
                    "Amazon",
                    "Pfizer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-07",
            "original_text": "Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?",
            "features": {
                "keywords": [
                    "Disappointment",
                    "Glaxo",
                    "GSK",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]